Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial
Abstract Background: Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an epidemic period.Methods: We conducted a double-blind placebo-controlled randomized clinical trial in three hospitals in Barcelona, Spain. From 350 adult healthcare workers screened, we included 269 participants with no active or past SARS-CoV-2 infection (determined by a negative nasopharyngeal SARS-CoV-2 PCR and a negative serology against SARS-CoV-2). Participants allocated in the intervention arm (PrEP) received 400mg of hydroxychloroquine daily the first four consecutive days and subsequently, 400mg weekly during the study period. Participants in the control group followed the same treatment schedule with placebo tablets. Results: 52.8% (142/269) of participants were in the hydroxychloroquine arm and 47.2% (127/269) in the placebo arm. Both groups showed similar proportion of participants experiencing at least one adverse event (AE) (p=0.548). No serious AEs were reported. Almost all AEs (96.4%, 106/110) were mild. Only mild gastrointestinal symptoms were significantly higher in the hydroxychloroquine arm compared to the placebo arm (27.4% (39/142) vs 15.7% (20/127), p=0.041). Given the national epidemic incidence decay, only one participant in each group was COVID-19 diagnosed. Consequently, our study design deemed underpowered to evaluate any benefit regarding PrEP efficacy.Conclusions: First month follow-up analysis displayed that PrEP with hydroxychloroquine at low doses is safe.Trial registration: This trial was registered at clinicaltrials.gov (NCT04331834) on April 2nd 2020. https://clinicaltrials.gov/ct2/show/NCT04331834?term=NCT04331834&draw=2&rank=1.
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ResearchSquare.com - (2021) vom: 13. Apr. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grau-Pujol, Berta [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-350749/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034769153 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034769153 | ||
| 003 | DE-627 | ||
| 005 | 20230429193705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-350749/v1 |2 doi | |
| 035 | |a (DE-627)XRA034769153 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-350749/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Grau-Pujol, Berta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an epidemic period.Methods: We conducted a double-blind placebo-controlled randomized clinical trial in three hospitals in Barcelona, Spain. From 350 adult healthcare workers screened, we included 269 participants with no active or past SARS-CoV-2 infection (determined by a negative nasopharyngeal SARS-CoV-2 PCR and a negative serology against SARS-CoV-2). Participants allocated in the intervention arm (PrEP) received 400mg of hydroxychloroquine daily the first four consecutive days and subsequently, 400mg weekly during the study period. Participants in the control group followed the same treatment schedule with placebo tablets. Results: 52.8% (142/269) of participants were in the hydroxychloroquine arm and 47.2% (127/269) in the placebo arm. Both groups showed similar proportion of participants experiencing at least one adverse event (AE) (p=0.548). No serious AEs were reported. Almost all AEs (96.4%, 106/110) were mild. Only mild gastrointestinal symptoms were significantly higher in the hydroxychloroquine arm compared to the placebo arm (27.4% (39/142) vs 15.7% (20/127), p=0.041). Given the national epidemic incidence decay, only one participant in each group was COVID-19 diagnosed. Consequently, our study design deemed underpowered to evaluate any benefit regarding PrEP efficacy.Conclusions: First month follow-up analysis displayed that PrEP with hydroxychloroquine at low doses is safe.Trial registration: This trial was registered at clinicaltrials.gov (NCT04331834) on April 2nd 2020. https://clinicaltrials.gov/ct2/show/NCT04331834?term=NCT04331834&draw=2&rank=1 | ||
| 700 | 1 | |a Camprubí, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Marti-Soler, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Pardos, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Carreras-Abad, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Andrés, Maria Velasco de |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Elisabet |e verfasserin |4 aut | |
| 700 | 1 | |a Muelas-Fernandez, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Jullien, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Barilaro, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Ajanovic, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Redondo, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Cortes-Serra, Núria |e verfasserin |4 aut | |
| 700 | 1 | |a Roldán, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Arcos, Ana Artes de |e verfasserin |4 aut | |
| 700 | 1 | |a Mur, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Domingo, Pere |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Guinovart, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Jose |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2021) vom: 13. Apr. |
| 773 | 1 | 8 | |g year:2021 |g day:13 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-350749/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 13 |c 04 | ||
| 953 | |2 045F |a 570 | ||